Lantheus Holdings' LNTH-2513 Wins SNMMI's 2026 Image of the Year for DVT Diagnosis

Lantheus Holdings achieves significant milestone with its investigational PET imaging agent LNTH-2513 (18F-GP1), awarded SNMMI’s prestigious 2026 “Image of the Year.” The accolade highlights clinical data that proves the agent’s high diagnostic accuracy in detecting acute deep vein thrombosis (DVT) and associated pulmonary embolism. This recognition reinforces Lantheus's innovative approach within the radiopharmaceuticals sector, especially in expanding its platelet-targeted imaging capabilities. The success of LNTH-2513 positions Lantheus to diversify its endeavors, shifting beyond oncology towards a prominent focus on thrombotic disease evaluation.

Expanding Horizons in Medical Imaging

This strategic pivot opens new avenues for Lantheus, potentially enhancing its product offerings and market share in the medical imaging segment. The increased attention to DVT and associated conditions aligns with growing recognition of the importance of accurate diagnostics in managing thrombotic diseases. As healthcare professionals highlight the need for more effective imaging solutions, Lantheus's advancements set the stage for a competitive edge in the market.

Boosted Visibility Ahead

The award from SNMMI not only validates the clinical efficacy of LNTH-2513 but also boosts Lantheus's visibility in the healthcare landscape. The company plans to leverage this recognition as it prepares for upcoming industry events, such as the Goldman Sachs healthcare conference. This visibility could attract further interest from investors and stakeholders, showcasing Lantheus's potential for growth in an expanding arena of diagnostic imaging agents.